Tag Archive
FDA Approves Bimatoprost 0.01% Eye Drops For Elevated Intraocular Pressure
approved bimatoprost 0.01% ophthalmic solution for the first-line treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Medscape Medical News
Association between primary open-angle glaucoma (POAG) and WDR36 sequence variance in Italian families affected by POAG
Background/aims To assess the involvement of WDR36 sequence variance in primary open-angle glaucoma (POAG) in Italian patients. Methods A cohort of 34 Italian families affected by POAG was analysed by denaturing high-performance liquid
Cochrane Eyes and Vision Group
Neuroprotection for treatment of glaucoma in adults Glaucoma is a heterogeneous group of conditions involving progressive damage to the optic nerve, deterioration of retinal ganglion cells and ultimately visual-field loss. It is a leading cause
Open-angle glaucoma and ocular perfusion
Unit, Department of Ophthalmology, Hacettepe University, School of Medicine, Ankara, Turkey Correspondence to Dr A G P Konstas, Glaucoma Unit, 1st University Department of Ophthalmology, AHEPA Hospital, 1 Kyriakidi Str, Thessaloniki 546 36, Greece;
Surgical Revision of Dysfunctional Filtration Blebs With Bleb Preservation, Sliding Conjunctival Flap and Fibrin Glue
This article explores some of the options available in glaucoma filtration surgery to improve intraocular pressure. Eye
Allergan Gets FDA Approval For Lumigan 0.01% As First-Line Therapy To Reduce Elevated IOP In Glaucoma Patients – Update
0.01% as a first-line therapy indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Lumigan or bimatoprost ophthalmic solution 0.01% is an optimized reformulation of Lumigan 0.03%. The
Allergan, Inc. Receives FDA Approval for LUMIGAN(R) 0.01% as First-Line Therapy Indicated for…
01% as a first-line therapy indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. LUMIGAN(R) 0.01% is an optimized reformulation of LUMIGAN(R) (bimatoprost ophthalmic solution)
Allergan Gets FDA Approval For LUMIGAN 0.01% As First-line Therapy For Reduction Of Elevated Intraocular Pressure In Glaucoma Patients – Quick Facts
0.01% as a first-line therapy indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. LUMIGAN 0.01% is an optimized reformulation of LUMIGAN 0.03%. LUMIGAN 0.01% is a once-daily
Allergan, Inc. Receives FDA Approval for LUMIGAN® 0.01% as First-Line Therapy Indicated for the Reduction of Elevated Intraocular Pressure in Glaucoma Patients
01% as a first-line therapy indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. LUMIGAN® 0.01% is an optimized reformulation of LUMIGAN® (bimatoprost ophthalmic solution)
